PDS Biotech Launches Phase 3 Trial of Versamune® in HPV16+ Head and Neck Cancer
PDS Biotechnology Corporation has launched VERSATILE-003, a Phase 3 clinical trial for its immunotherapy drug, Versamune® HPV. The trial...
AskBio Doses First Limb-Girdle Muscular Dystrophy Patient
AskBio, a Bayer subsidiary, announced the advancement of its Phase 1/Phase 2 LION-CS101 clinical trial for AB-1003, a gene...
MindRank’s MRANK-106 Gets FDA Clearance for Oncology Trials
MindRank, an AI-driven drug discovery company, has received FDA Investigational New Drug (IND) application clearance for MRANK-106. MRANK-106 is...
Promising Rhenium-186 Obisbemeda GBM Phase 1 Results in Nature Communications
Plus Therapeutics announced positive Phase 1 clinical trial results for Rhenium (¹⁸⁶Re) Obisbemeda in treating recurrent glioblastoma (GBM), published...
Briumvi Data at AAN 2025 Meeting: TG Therapeutics MS Treatment
TG Therapeutics announced upcoming presentations of Briumvi (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of...
Givastomig Phase 1b Study Sees Accelerated Progress
I-Mab, a global biotech company, announced the completion of enrollment, ahead of schedule, in the first dose expansion cohort...
BioXcel’s Serenity Trial: At-Home Agitation Treatment
BioXcel Therapeutics has reached 33% enrollment (67 patients) in its 200-patient Phase 3 SERENITY At-Home trial for BXCL501 (dexmedetomidine...
Regeneron and Sanofi: Dupixent® Bullous Pemphigoid Data at AAD
Regeneron and Sanofi announced positive Phase 2/3 trial results for Dupixent (dupilumab) in treating moderate-to-severe bullous pemphigoid (BP), a...
Late-Breaking ESK-001 Phase 2 Data Presented at AAD Meeting
Alumis announced positive 52-week data from the open-label extension of its Phase 2 STRIDE trial for ESK-001, an oral...
Study Shows Increased Cardiometabolic Risk After Switching to Integrase Inhibitors
The AIDS Clinical Trials Group (ACTG) presented data from the REPRIEVE study at the 2025 Conference on Retroviruses and...